- Home
- FTW vs STRO Comparison
FTW vs STRO Comparison
Compare FTW & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FTW | STRO |
|---|---|---|
| Founded | 2017 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 283.9M | 332.8M |
| IPO Year | 2026 | 2018 |
Fundamental Metrics
Financial Performance| Metric | FTW | STRO |
|---|---|---|
| Price | $10.00 | $11.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 14 |
| Target Price | $16.00 | ★ $47.23 |
| AVG Volume (30 Days) | 90.8K | ★ 266.4K |
| Earning Date | 11-24-2026 | 11-05-2026 |
| Dividend Yield | ★ 13.64% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $38,419,000.00 |
| Revenue This Year | $32.44 | N/A |
| Revenue Next Year | $3.93 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.46 | $0.72 |
| 52 Week High | $17.20 | $43.85 |
Technical Indicators
Market Signals| Indicator | FTW | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 43.85 | 27.71 |
| Support Level | $9.48 | $10.52 |
| Resistance Level | $10.54 | $16.99 |
| Average True Range (ATR) | 0.23 | 1.22 |
| MACD | 0.06 | -0.22 |
| Stochastic Oscillator | 58.23 | 14.50 |
Price Performance
Historical ComparisonAbout FTW EQV Ventures Acquisition Corp. Class A Ordinary Shares
Presidio Production Co is an independent oil and natural gas company engaged in oil and gas exploration and production, with operations concentrated across the Western Anadarko Basin of Texas, Oklahoma, and Kansas. It oeprates in one reportable segment, which is engaged in the acquisition, development, exploration, and production of oil and natural gas properties. It derives its revenue from customers through the sale of oil, natural gas, and NGLs as well as other immaterial service contracts in United States.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.